Your browser doesn't support javascript.
loading
Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
Habbous, Steven; Przech, Sebastian; Martin, Janet; Garg, Amit X; Sarma, Sisira.
Afiliação
  • Habbous S; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada. Electronic address: steven_habbous@hotmail.com.
  • Przech S; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
  • Martin J; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada; Department of Anesthesia and Perioperative Medicine, Centre for Medical Evidence, Decision Integrity and Clinical Impact, London, Ontario, Canada.
  • Garg AX; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada; Division of Nephrology, London Health Sciences Centre, Western University, London, Ontario, Canada.
  • Sarma S; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
Value Health ; 21(3): 318-325, 2018 03.
Article em En | MEDLINE | ID: mdl-29566839
BACKGROUND: Phosphate binders are used to treat hyperphosphatemia among patients with chronic kidney disease (CKD). OBJECTIVES: To conduct an economic evaluation comparing calcium-free binders sevelamer and lanthanum with calcium-based binders for patients with CKD. METHODS: Effectiveness data were obtained from a recent meta-analysis of randomized trials. Effectiveness was measured as life-years gained and translated to quality-adjusted life-years (QALYs) using utility weights from the literature. A Markov model consisting of non-dialysis-dependent (NDD)-CKD, dialysis-dependent (DD)-CKD, and death was developed to estimate the incremental costs and effects of sevelamer and lanthanum versus those of calcium-based binders. A lifetime horizon was used and both costs and effects were discounted at 1.5%. All costs are presented in 2015 Canadian dollars from the Canadian public payer perspective. Results of probabilistic sensitivity analysis were presented using cost-effectiveness acceptability curves. Sensitivity analyses were conducted for risk pooling methods, omission of dialysis costs, and persistence of drug effects on mortality. RESULTS: Sevelamer resulted in an incremental cost-effectiveness ratio of $106,522/QALY for NDD-CKD and $133,847/QALY for DD-CKD cohorts. Excluding dialysis costs, sevelamer was cost-effective in the NDD-CKD cohort ($5,847/QALY) and the DD-CKD cohort ($11,178/QALY). Lanthanum was dominated regardless of whether dialysis costs were included. CONCLUSIONS: Existing evidence does not clearly support the cost-effectiveness of non-calcium-containing phosphate binders (sevelamer and lanthanum) relative to calcium-containing phosphate binders in DD-CKD patients. Our study suggests that sevelamer may be cost-effective before dialysis onset. Because of the remaining uncertainty in several clinically relevant outcomes over time in DD-CKD and NDD-CKD patients, further research is encouraged.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carbonato de Cálcio / Análise Custo-Benefício / Insuficiência Renal Crônica / Hiperfosfatemia / Sevelamer / Lantânio Tipo de estudo: Clinical_trials / Health_economic_evaluation / Systematic_reviews Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Value Health Assunto da revista: FARMACOLOGIA Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carbonato de Cálcio / Análise Custo-Benefício / Insuficiência Renal Crônica / Hiperfosfatemia / Sevelamer / Lantânio Tipo de estudo: Clinical_trials / Health_economic_evaluation / Systematic_reviews Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Value Health Assunto da revista: FARMACOLOGIA Ano de publicação: 2018 Tipo de documento: Article